PharmaEngine Stock

PharmaEngine EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of PharmaEngine (4162.TWO) as of Aug 1, 2026 is 21.66. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 4.49 — a change of 382.55% (higher).

EV/EBIT

21.66

YoY

382.55%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of PharmaEngine is 2026 21.66 . EV/EBIT (Enterprise Value to EBIT) of PharmaEngine was 2025 4.49 . It decreases by 382.55% higher compared to the previous year.

The PharmaEngine EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
203.60 base
Jan 1, 2020
10.88 base
Jan 1, 2021
19.09 base
Jan 1, 2022
45.77 base
Jan 1, 2023
54.67 base
Jan 1, 2024
6.32 base
Jan 1, 2025
23.78 base
Jan 1, 2026 (e)
13.12 base
YEARPRICE-TO-EBIT
2026 est 13.12
2025 23.78
2024 6.32
2023 54.67
2022 45.77
2021 19.09
2020 10.88
2019 203.60
2018 395.27
2017 44.30
2016 27.40
2015 75.08
2014 411.29
2013 -141.27
2012 278.91
2011 -
2010 -
2009 -
2008 -
Access this data via the Eulerpool API
Get Free API Key

PharmaEngine Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides PharmaEngine's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates PharmaEngine's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots PharmaEngine's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if PharmaEngine grows earnings faster than its peers.

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

EV/EBIT (Enterprise Value to EBIT) of PharmaEngine is 21.66 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — PharmaEngine

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — PharmaEngine